0001193805-20-000285.txt : 20200303
0001193805-20-000285.hdr.sgml : 20200303
20200303190744
ACCESSION NUMBER: 0001193805-20-000285
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mond James
CENTRAL INDEX KEY: 0001554537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 20684907
MAIL ADDRESS:
STREET 1: 65 COMMERCE WAY
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
e619419_4-mond.xml
X0306
4
2020-02-28
0
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001554537
Mond James
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
RAMSEY
NJ
07446
0
1
0
0
EVP, CSO and CMO
Common Stock
2020-02-28
4
A
0
40000
0
A
62174
D
Employee Stock Option (right to buy)
2.915
2020-02-28
4
A
0
100000
0
A
2030-02-28
Common Stock
100000
100000
D
These shares represent restricted stock units ("RSUs"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.
Includes (i) 40,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 22,174 shares of common stock owned by the reporting person.
The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.
/s/ James Mond, by Brian Lenz as Attorney-in-fact
2020-03-03